Home>
Stocks>
Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd (KREBSBIO)

₹74.75▲4.77%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Krebs Biochemicals & Industries Ltd share Performance

₹70.1
₹76.65
₹74.75
6.22%
Low
Day's Volatility:8.76%
High
2.54%
₹59.2
₹93.95
₹74.75
20.80%
Low
52 Weeks Volatility:46.49%
High
25.69%

Returns %
1 Month Return	5.47 %
3 Month Return	-4.1 %
1 Year Return	1.49 %

Market Stats
Previous Close	₹71.35
Open	₹71.90
Volume	26.62K
Upper Circuit	-
Lower Circuit	-
Market Cap	₹153.83Cr

Company Information

Krebs Biochemicals Industries Ltd. (KBIL) is a fermentation-based active pharmaceutical ingredient (API) manufacturer. Established in 1991, KBL has grown to a capacity of 150 TPA since launching its commercial operations in 1994. KBL has developed global capabilities in fermentation technology, resulting in successful launches over a two-year period (200102) of Vitamin CIP Grade via fermentation. The company has ISO 9002 certifications for its unit I at Nellore and produces and markets Lovastatin, Simvastatin, and Vitamin C. KBL is also in the process of building a cogeneration power plant at unit II. It has also successfully bidded for Nannapaneni Venkatrao Cooperative Sugars Ltd located at Jampani, Guntur District, Andhra Pradesh in December 2003.

Share Price: ₹74.75 per share as on 02 May, 2024 04:01 PM
Market Capitalisation: ₹153.83Cr as of today
Listing date: 28 Aug, 1995
Chairperson Name: R T Ravi

Organisation	Krebs Biochemicals & Industries Ltd
Headquarters	Hyderabad
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Fundamentals of Krebs Biochemicals & Industries Ltd

Insights on Krebs Biochemicals & Industries Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
FII Holding Unchanged
Foreign Institutions holdings remained unchanged at 0.49% of holdings in Mar 2024 quarter
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 72.74% of holdings in Mar 2024 quarter
NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 26.76% of holdings in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.9% return, outperforming this stock by 172.9%
NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 54.4% return, outperforming this stock by 52.9%
NEGATIVE IMPACT
Price Dip
In the last 3 years, KREBSBIO stock has moved down by -45.0%